News
ERS Genomics and Fasmac Reach CRISPR/Cas9 Commercialisation Agreement for Japan
Oct 27 2020
ERS Genomics Ltd, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr Emmanuelle Charpentier, has announced it has signed an agreement with Fasmac Co, Ltd of Japan. Under the terms of the non-exclusive agreement Fasmac acquires the right to use CRISPR/Cas9 technology and commercialise tools and reagents associated with it.
Established in 2001, Fasmac provides food analysis and biotechnology products and services including DNA/RNA synthesis products, DNA sequencing services, food testing services and genetic analysis reagents and kits.
"Our portfolio of Japanese companies taking license to the CRISPR/Cas9 technology is growing rapidly, and we are very pleased to be working with Fasmac," said Eric Rhodes, CEO of ERS Genomics. "We look forward to watching the company as it grows in this space and provides a valuable contribution to the genome editing field."
Dr Satoshi Futo, CEO of Fasmac commented: “Having access to advanced technologies such as CRISPR/Cas9 is very important to us, as we strive to create value for our customers both in Japan and overseas. The license from ERS will allow us to expand our already broad offering.”
Financial details of the agreement are not disclosed.
Digital Edition
Lab Asia 32.1 Feb 2025
February 2025
Chromatography Articles - Comparing volumetric and thermal flowmeters for assessing and validating liquid chromatography performance Mass Spectrometry & Spectroscopy Articles - The importa...
View all digital editions
Events
SPS Smart Production Solutions Guangzhou
Feb 25 2025 Guanghzou, China
Feb 25 2025 Amsterdam, Netherlands
Feb 27 2025 Kathmandu, Nepal
Mar 01 2025 Boston, MA, USA
Mar 02 2025 Bethesda, MD, USA